Ubs Group Ag Fate Therapeutics Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Ubs Group Ag holds 404,279 shares of FATE stock, worth $897,499. This represents 0.0% of its overall portfolio holdings.

Number of Shares

404,279

Previous 164,356 145.98%

Holding current value

$897,499

Previous $539,000 162.34%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.12 - $5.57 $748,559 - $1.34 Million	239,923 Added 145.98%	404,279 $1.41 Million
Q2 2024 Aug 13, 2024	SELL	$3.26 - $7.08 $911,802 - $1.98 Million	-279,694 Reduced 62.99%	164,356 $539,000
Q1 2024 May 13, 2024	BUY	$3.54 - $8.35 $947,817 - $2.24 Million	267,745 Added 151.86%	444,050 $3.26 Million
Q4 2023 Feb 09, 2024	BUY	$1.65 - $3.94 $180,831 - $431,804	109,595 Added 164.29%	176,305 $659,000
Q3 2023 Nov 09, 2023	SELL	$2.02 - $5.04 $389,811 - $972,599	-192,976 Reduced 74.31%	66,710 $141,000
Q2 2023 Aug 11, 2023	SELL	$4.76 - $6.59 $754,174 - $1.04 Million	-158,440 Reduced 37.89%	259,686 $1.24 Million
Q1 2023 May 12, 2023	BUY	$4.24 - $11.12 $535,151 - $1.4 Million	126,215 Added 43.24%	418,126 $2.38 Million
Q4 2022 Feb 08, 2023	BUY	$9.86 - $23.83 $2.85 Million - $6.9 Million	289,546 Added 12242.96%	291,911 $2.95 Million
Q3 2022 Nov 10, 2022	SELL	$21.04 - $36.06 $1.05 Million - $1.81 Million	-50,123 Reduced 95.49%	2,365 $53,000
Q2 2022 Aug 10, 2022	SELL	$17.78 - $42.39 $1.55 Million - $3.69 Million	-87,025 Reduced 62.38%	52,488 $1.3 Million
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $341,590 - $694,003	11,513 Added 8.99%	139,513 $5.41 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $4.86 Million - $6.53 Million	101,515 Added 383.29%	128,000 $7.49 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $644,679 - $1.04 Million	10,877 Added 69.69%	26,485 $1.57 Million
Q2 2021 Aug 13, 2021	SELL	$67.25 - $92.52 $1.98 Million - $2.72 Million	-29,388 Reduced 65.31%	15,608 $1.35 Million
Q1 2021 May 12, 2021	SELL	$72.16 - $117.4 $3.08 Million - $5.02 Million	-42,725 Reduced 48.71%	44,996 $3.71 Million
Q4 2020 Feb 11, 2021	BUY	$38.09 - $100.95 $3.08 Million - $8.16 Million	80,793 Added 1166.18%	87,721 $7.98 Million
Q3 2020 Nov 12, 2020	BUY	$30.41 - $40.5 $52,213 - $69,538	1,717 Added 32.95%	6,928 $277,000
Q2 2020 Jul 31, 2020	SELL	$20.21 - $35.23 $36,923 - $64,365	-1,827 Reduced 25.96%	5,211 $179,000
Q1 2020 May 01, 2020	SELL	$17.28 - $31.88 $772,139 - $1.42 Million	-44,684 Reduced 86.39%	7,038 $156,000
Q4 2019 Feb 14, 2020	SELL	$13.39 - $20.73 $1.6 Million - $2.48 Million	-119,783 Reduced 69.84%	51,722 $1.01 Million
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $2.06 Million - $2.99 Million	133,074 Added 346.27%	171,505 $2.66 Million
Q2 2019 Aug 14, 2019	BUY	$15.61 - $20.44 $450,769 - $590,245	28,877 Added 302.25%	38,431 $780,000
Q1 2019 May 14, 2019	SELL	$13.15 - $18.71 $1.03 Million - $1.47 Million	-78,398 Reduced 89.14%	9,554 $168,000
Q4 2018 Feb 14, 2019	BUY	$11.48 - $16.98 $661,730 - $978,761	57,642 Added 190.17%	87,952 $1.13 Million
Q3 2018 Nov 14, 2018	SELL	$8.75 - $16.29 $622,125 - $1.16 Million	-71,100 Reduced 70.11%	30,310 $494,000
Q2 2018 Aug 14, 2018	BUY	$9.16 - $13.48 $845,028 - $1.24 Million	92,252 Added 1007.34%	101,410 $1.15 Million
Q1 2018 May 15, 2018	BUY	$6.3 - $13.77 $19,630 - $42,907	3,116 Added 51.57%	9,158 $89,000
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $16,910 - $28,498	4,292 Added 245.26%	6,042 $37,000
Q3 2017 Nov 14, 2017	SELL	$2.6 - $4.31 $108,875 - $180,481	-41,875 Reduced 95.99%	1,750 $7,000
Q2 2017 Aug 14, 2017	BUY	N/A	43,625	43,625 $141,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $215M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account